Sembragiline (EVT302) is used for the research of Alzheimer's disease (AD), particularly in patients exhibiting increased MAO-B activity; it acts as a potent, selective, and reversible inhibitor of monoamine oxidase B (MAO-B), thereby increasing the concentration of dopamine and other amine neurotransmitters in the brain and reducing the formation of toxic reactive oxygen species (ROS) implicated in AD pathology.